News coverage about GTX (NASDAQ:GTXI) has trended somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GTX earned a news impact score of 0.11 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.3026419670381 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of GTX (NASDAQ:GTXI) opened at $13.10 on Tuesday. GTX has a twelve month low of $2.73 and a twelve month high of $13.35.

GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.25). equities analysts predict that GTX will post -1.61 earnings per share for the current year.

A number of brokerages have recently weighed in on GTXI. Robert W. Baird began coverage on shares of GTX in a report on Tuesday, November 21st. They set an “outperform” rating and a $17.00 price target for the company. Stifel Nicolaus began coverage on shares of GTX in a report on Thursday, November 9th. They set a “buy” rating for the company.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at

About GTX

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Insider Buying and Selling by Quarter for GTX (NASDAQ:GTXI)

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with's FREE daily email newsletter.